CAS |
No.142880-36-2 |
中文名称 |
伊洛马司他 |
英文名称 |
Ilomastat |
别名 |
伊洛马司他;伊诺马司他; |
分子式 |
C20H28N4O4 |
分子量 |
388.46 |
溶解性 |
Soluble in DMSO(Need ultrasonic) |
纯度 |
≥98% |
外观(性状) |
Solid |
储存条件 |
Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year |
MDL |
MFCD00917040 |
SMILES |
CC(C)C[C@H](CC(=O)NO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NC |
InChIKey |
NITYDPDXAAFEIT-DYVFJYSZSA-N |
InChI |
InChI=1S/C20H28N4O4/c1-12(2)8-13(10-18(25)24-28)19(26)23-17(20(27)21-3)9-14-11-22-16-7-5-4-6-15(14)16/h4-7,11-13,17,22,28H,8-10H2,1-3H3,(H,21,27)(H,23,26)(H,24,25)/t13-,17+/m1/s1 |
PubChem CID |
132519 |
靶点 |
MMP |
通路 |
Metabolic Enzyme&Protease |
背景说明 |
Ilomastat是一种有效、广谱的基质金属蛋白酶 (MMP) 抑制剂。 |
生物活性 |
Ilomastat (GM6001) is a potent and broad spectrum matrix metalloprotease (MMP) inhibitor, inhibits MMPs (IC50s, 1.5 nM for MMP-1; 1.1 nM for MMP-2; 1.9 nM for MMP-3; 0.5 nM for MMP-9), with a Ki of 0.4 nM for human skin fibroblast collagenase (MMP-1).[1-5] |
IC50 |
Fibroblast collagenase 0.4 nM (Ki, Human skin) MMP-1 1.5 nM (IC50) MMP-2 1.1 nM (IC50) MMP-3 1.9 nM (IC50) MMP-9 0.5 nM (IC50) Thermolysin 20 nM (Ki) Eastase 20 nM (Ki)[1-5] |
In Vitro |
Ilomastat (GM6001) inhibits human skin fibroblast collagenase, thermolysin and elastase with Kis?of 0.4 nM, 20 nM, 20 nM, resepctively[1].?Ilomastat (0.1-10 nM) inhibits gelatinase A and gelatinase B produced by T-cells. Ilomastat inhibits T-cell homing[4]. |
In Vivo |
Ilomastat (GM6001) (400 μg/mL) inhibits corneal ulceration after severe alkali injury in animals[2]. Ilomastat (GM6001) significantly suppresses intimal hyperplasia and intimalcollagen content. Ilomastat increases lumen area in stented arteries, shows no activity on proliferation rates in rabbit model after stenting[3]. |
动物实验 |
To assess the effects of MMP inhibition, animals are given daily injections of either vehicle (“placebo group”) or Ilomastat (GM6001) (100 mg/kg per day as subcutaneous suspension), beginning one day before the second injury until seven days after the procedure. Ilomastat (GM6001) is a nonspecific hydroxamic acid-based MMPI with potent inhibitory activity against collagenase, gelatinases and stromelysin. Animals are euthanized at either 1 week or 10 weeks after the second injury. |
数据来源文献 |
[1]. Grobelny D, et al. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry. 1992 Aug 11;31(31):7152-4. [2]. Schultz GS, et al. Treatment of alkali-injured rabbit corneas with a synthetic inhibitor of matrix metalloproteinases. Invest Ophthalmol Vis Sci. 1992 Nov;33(12):3325-31. [3]. Li C, et al. Arterial repair after stenting and the effects of GM6001, a matrix metalloproteinase inhibitor. J Am Coll Cardiol. 2002 Jun 5;39(11):1852-8. [4]. Leppert D, et al. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol. 1995 May 1;154(9):4379-89. [5]. Yamamoto M, et al. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket. J Med Chem. 1998 Apr 9;41(8):1209-17. |
规格 |
1mg 2mg 5mg 10mg 25mg |
单位 |
瓶 |